CD47 and cardiovascular disorder: Therapeutic agents that block TSP1/CD47 signaling improve the sensitivity to NO-mediated vasodilators in cardiovascular diseases in humans [141] as well as in pigs and rodents, where these agents improve blood flow and hyperemia in response to ischemia [119,142,143].